ACH
ACCENDRA HEALTH INC/VA/
NYSE · Healthcare · Medical - Distribution · US
$0.27
−4.14%Nov 3, 2026, 22:10 UTC
Accendra Health said Perry A. Bernocchi will transition from executive vice president and chief operating officer to strategic advisor to the chief executive officer by mutual agreement, effective November 1, 2026.
Nov 2, 2026, 11:52 UTC
Accendra Health amended its receivables purchase agreement with PNC Bank, extending the scheduled termination date until October 2029 and revising account-control provisions and reporting obligations.
Source:Oct 30, 2026, 20:45 UTC
Accendra Health said it intends to submit a business plan and return to compliance with the NYSE listing standard.
Source:Oct 30, 2026, 20:45 UTC
Accendra Health said it received an NYSE notice that it was not in compliance with continued listing standards requiring average market capitalization and stockholders’ equity of at least $50 million.
Source:Oct 9, 2026, 20:15 UTC
The NYSE notified ACCENDRA HEALTH INC/VA/ that it was not in compliance with Section 802.01C because of its share price; the company said it would consider alternatives to regain compliance, including a reverse stock split subject to stockholder approval.
Source:Sep 28, 2026, 21:24 UTC
Accendra Health Inc. announced that Kenneth Gardner-Smith will succeed Edward A. Pesicka as President and Chief Executive Officer effective October 5, 2026, with Pesicka retiring from the CEO and director roles and transitioning to an advisory consulting arrangement.
Sep 17, 2026, 10:41 UTC
Accendra Health Inc. appointed Kenneth Gardner-Smith as President and Chief Executive Officer, succeeding retiring Edward A. Pesicka, and named Scott Lloyd as Chief Commercial Officer effective October 5, 2026.
Source:Aug 17, 2026, 10:30 UTC
Accendra Health announced it will not implement an at-the-market equity issuance program due to recent market conditions, abandoning the plan to issue modest amounts of equity over time to reduce debt.
Source:Aug 10, 2026, 10:50 UTC
Accendra Health's Board of Directors adopted a Section 382 Rights Agreement (Tax Asset Preservation Plan) to protect its net operating loss carryforwards and other tax attributes, announced on August 10, 2026.
Source:Aug 10, 2026, 10:45 UTC
Accendra Health reported its financial results for the second quarter ended June 30, 2026, reflecting continuing operations from its Patient Direct segment.
Source:Jun 15, 2026, 00:00 UTC
Accendra Health Inc amended its existing 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030, eliminating substantially all affirmative and negative covenants and certain events of default, effective June 15, 2026 after receiving sufficient note holder consents.
Jun 14, 2026, 05:57 UTC
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) acquires an additional 12% stake in Arabian Medical Products Manufacturing Co. (ENAYAH) from Accendra Health, Inc., increasing its ownership from 51% to 63%.
Source:Jun 10, 2026, 10:30 UTC
Accendra Health announced early results of offers to exchange its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030.